Sorafenib/Docetaxel Dose Escalation Trial

This study has been completed.
Onyx Pharmaceuticals
Information provided by:
Bayer Identifier:
First received: November 21, 2007
Last updated: May 22, 2013
Last verified: May 2013
The purpose of this study is to: 1.) Evaluate how your body reacts to sorafenib when taken daily (continuously) in combination with docetaxel given every 3 weeks, and to determine the safety of the two drugs together.2.) Measure your blood levels of sorafenib and docetaxel at specific times after taking the medications.

Condition Intervention Phase
Drug: Sorafenib (Nexavar, BAY43-9006)
Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase I Dose Escalation Study With Sorafenib Administered Continuously in Combination With Docetaxel Administered Once Every Three Weeks in Patients With Advanced Solid Tumors.

Resource links provided by NLM:

Further study details as provided by Bayer:

Primary Outcome Measures:
  • To determine the safety, maximum tolerated dose and dose-limiting toxicities of oral sorafenib [ Time Frame: 6 weeks ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • To determine if there is a pharmacokinetic interaction between sorafenib and docetaxel when they are administered together [ Time Frame: 6 weeks ] [ Designated as safety issue: Yes ]

Enrollment: 17
Study Start Date: November 2007
Study Completion Date: March 2009
Primary Completion Date: March 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Arm 1 Drug: Sorafenib (Nexavar, BAY43-9006)
Sorafenib 400mg by mouth daily in combination with docetaxel 60mg/m2 IV once every 3 weeks


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age greater than or equal to 18 years
  • Advanced histological or cytological documentation of cancer
  • At least one evaluable lesion
  • ECOG Performance Status of 0 or 1
  • No more than one prior chemotherapy regimen (prior adjuvant therapy, immunotherapy or hormone treatment are allowed and not restricted)
  • Life expectancy of at least 12 weeks
  • No previous exposure to docetaxel or sorafenib
  • Adequate bone marrow, liver and renal function as assessed by the following:

    • Hemoglobin greater than or equal to 9.0 g/dL
    • Absolute neutrophil count (ANC) greater than or equal to 2,500/mm3
    • Platelet count greater than or equal to 100,000/mm3 Hepatic
    • Total Bilirubin less than or equal to ULN
    • AST, ALT and Alkaline Phosphatase less than 1.5x ULN.
    • PT-INR/PTT less than 1.5 x ULN (Patients who are being prophylactically anti coagulated with an agent such as coumadin or heparin will be allowed to participate provided that the INR less than 1.5. In addition, these patients must be monitored at appropriate intervals throughout study)
    • Serum creatinine less than or equal to 1.5 x upper limit of normal

Exclusion Criteria:

  • Myocardial infarction or symptomatic coronary artery disease (severe or unstable angina) within 6 months prior to screening
  • Active clinically serious infections (> Grade 2 NCI-CTCAE Version 3.0)
  • Uncontrolled seizure disorder. Use of cytochrome P450 enzyme-inducing antiepileptic drugs (phenytoin, carbamazepine or phenobarbital) is not allowed
  • Uncontrolled hypertension defined as systolic blood pressure > 150 mmHg or diastolic pressure > 90 mmHg, despite optimal medical management
  • Known human immunodeficiency virus (HIV) infection or chronic hepatitis B or C
  • Peripheral neuropathy > Grade 1
  • Thrombotic or embolic events (such as transient ischemic attacks, myocardial infarction, pulmonary embolus), within 6 months prior to screening
  • Major surgery, open biopsy or significant traumatic injury within 4 weeks of first study treatment
  • Pregnant or breast feeding women
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00562523

United States, Florida
Tampa, Florida, United States, 33612
United States, Pennsylvania
Philadelphia, Pennsylvania, United States, 19111-2497
Sponsors and Collaborators
Onyx Pharmaceuticals
Study Director: Bayer Study Director Bayer
  More Information

Additional Information:
Responsible Party: Head Clinical Pharmacology, Bayer HealthCare Pharmaceuticals Inc. Identifier: NCT00562523     History of Changes
Other Study ID Numbers: 12438 
Study First Received: November 21, 2007
Last Updated: May 22, 2013
Health Authority: United States: Food and Drug Administration

Keywords provided by Bayer:

Additional relevant MeSH terms:
Antimitotic Agents
Antineoplastic Agents
Enzyme Inhibitors
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Protein Kinase Inhibitors
Tubulin Modulators processed this record on May 26, 2016